Loading...
Market
Will Eli Lilly's stock rise 10% within a month of Mounjaro's HK launch?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock price data from financial market platforms like Bloomberg or Yahoo Finance
Story
Eli Lilly Gets Hong Kong Approval to Launch Mounjaro, First Weight-Loss Drug in China Region
Oct 28, 2024, 01:17 AM
Eli Lilly & Co. is set to launch its blockbuster weight-loss drug Mounjaro in Hong Kong by the end of this year, following approval from the Hong Kong government, Bloomberg News reported. Mounjaro, also known as tirzepatide, is approved for weight management and type 2 diabetes. This launch will make Mounjaro the first weight-loss drug available for sale in the China region, potentially tapping into a significant market across the border. The drug will be available in Kwikpen form.
View original story
Similar markets
Under $50 million • 25%
$50-$100 million • 25%
$100-$150 million • 25%
Over $150 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
